Short Interest in Aclarion, Inc. (NASDAQ:ACON) Declines By 6.0%

Posted by MarketBeat News on Sep 30th, 2024

Aclarion, Inc. (NASDAQ:ACON – Get Free Report) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 279,800 shares, a decline of 6.0% from the August 31st total of 297,700 shares. Based on an average daily trading volume, of 575,200 shares, the short-interest ratio is currently 0.5 days. Currently, 3.0% of the company’s shares are sold short.

Aclarion Price Performance

Aclarion stock opened at $0.18 on Monday. Aclarion has a 1 year low of $0.16 and a 1 year high of $9.90. The firm has a 50-day moving average of $0.23 and a two-hundred day moving average of $0.28.

Aclarion (NASDAQ:ACON – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. Aclarion had a negative net margin of 10,967.15% and a negative return on equity of 910.84%. The business had revenue of $0.01 million during the quarter. Equities analysts forecast that Aclarion will post -0.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Aclarion

Want More Great Investing Ideas?

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC acquired a new position in shares of Aclarion, Inc. (NASDAQ:ACON – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 1.40% of Aclarion as of its most recent SEC filing. Institutional investors and hedge funds own 7.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets reissued a “buy” rating and issued a $1.50 price objective (down from $1.60) on shares of Aclarion in a research report on Monday, August 26th.

View Our Latest Analysis on Aclarion

About Aclarion

(Get Free Report)

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.